How long should a perimenopause supplement take to work?

Q: How long should I take a perimenopause supplement before deciding if it works?

The standard clinical trial window for perimenopause supplements is 8 to 12 weeks. The CONCRET-MENOPA trial, which studied creatine HCl in perimenopausal and menopausal women, ran for eight weeks. Citicoline research measuring frontal lobe changes ran for six weeks. pine bark trials in perimenopausal women ran for eight weeks to six months. Evaluating a supplement at fewer than eight weeks means you are outside the research window used to detect an effect.

Q: Why do supplement trials choose 8 or 12 weeks specifically?

Eight weeks gives researchers enough time for a nutrient to accumulate in target tissues, alter a physiological process, and produce a statistically detectable change in a measured outcome. Shorter trials risk capturing noise rather than signal. Twelve weeks is used when the mechanism requires longer accumulation — for example, changes in brain creatine stores or structural changes to cell membranes. The duration reflects the biology of the ingredient, not arbitrary convenience.

Q: What is the difference between 'I feel better' and 'the research measured an effect'?

Clinical trials measure specific, quantifiable outcomes — reaction time, memory scores, blood markers, bioenergetics on brain imaging. These are objective. Krevie's content focuses on what trials measured, because that is what is verifiable and allows you to compare a product's dose against a published standard.

Q: If I take double the dose, will it work in half the time?

Not necessarily, and in some cases more is not better. In the Silveri et al. (2008) citicoline trial, the 500 mg dose produced larger effects than the 2,000 mg dose on frontal lobe bioenergetics. The CONCRET-MENOPA trial found that 1,500 mg creatine HCl outperformed the lower dose. Dose-response relationships are not always linear, which is one reason matching the research dose specifically matters more than simply maximising the dose.

Q: Does a supplement with more ingredients always perform better?

There is no evidence that a higher ingredient count improves outcomes. A product with twelve ingredients at sub-research doses will not outperform a product with four ingredients at their research doses. Outcome measures in published trials are tied to specific doses of specific ingredients.

By The Krevie Team | Last reviewed: May 2026

Most published clinical trials run for 8 to 12 weeks, and this is the standard window researchers use to measure whether a supplement has produced a measurable change. If you are evaluating a perimenopause supplement, eight weeks is the minimum meaningful assessment period. Shorter than that, and you are not comparing like with like against the trials the ingredient claims are based on.

What "time to effect" means in supplement research

When a supplement brand tells you how long their product takes to work, they are — or should be — drawing on the duration of the clinical trial that studied the key ingredient. That trial duration is not arbitrary. Researchers choose it based on the time required for a nutrient to accumulate in tissue, alter a biological process, and produce a measurable change in their chosen outcome measure.

The most common trial lengths in peer-reviewed supplement research are four weeks, eight weeks, and twelve weeks. Four-week trials tend to test acute or fast-acting effects. Eight-week trials are considered the standard for assessing sustained physiological change. Twelve-week trials are used when the mechanism of action operates slowly — for example, when an ingredient needs to build up in the brain rather than simply circulate in blood plasma.

The practical implication for anyone taking a perimenopause supplement is straightforward: if the ingredient in your product was studied in an eight-week trial, judging that product at week three is not a fair test. You are not in the window the researchers used to detect an effect.

This matters because "I've been taking it for a few months and I'm not sure it's working" is one of the most common things women say about perimenopause supplements. The question that follows — almost never asked — is: compared to what? What was the trial duration for each ingredient? What was the measured outcome? What would "working" actually look like in a clinical setting?

What the research shows

Here are the specific trial durations for three ingredients commonly included in perimenopause supplements, and what the research actually measured at those time points.

Creatine HCl — 8 weeks (CONCRET-MENOPA, 2026)

Korovljev et al. (2026) conducted a randomised controlled trial — the CONCRET-MENOPA trial — in 36 perimenopausal and menopausal women (mean age 50.1 years). Participants received medium-dose creatine hydrochloride at 1,500 mg per day, low-dose creatine hydrochloride at 750 mg per day, a combination supplement, or placebo for eight weeks. The primary measured outcomes included reaction time (using validated cognitive testing) and frontal brain creatine levels (measured by magnetic resonance spectroscopy). At eight weeks, the 1,500 mg creatine HCl group showed a 6.6% improvement in reaction time compared with 1.2% in the placebo group (p<0.01). Frontal brain creatine levels increased by 16.4% in the treatment group versus 0.9% in placebo (p<0.01). No severe adverse effects were reported. PubMed 40854087

Citicoline — 6 weeks for bioenergetics, 12 weeks for memory

Silveri, Dikan, Ross, Jensen, Kamiya, Kawada, Renshaw and Yurgelun-Todd (2008) used phosphorus magnetic resonance spectroscopy to measure frontal lobe bioenergetics in 16 healthy adults (mean age 47.3 years) who took citicoline (CDP-choline) at 500 mg or 2,000 mg daily for six weeks. At the six-week mark, those taking 500 mg showed a 7% increase in phosphocreatine, a 14% increase in beta-nucleoside triphosphates (predominantly ATP), and a 32% increase in the phosphocreatine-to-inorganic-phosphate ratio in the anterior cingulate cortex — all statistically significant. Effects were more pronounced at the lower 500 mg dose than at 2,000 mg. PubMed 18816480

A separate 12-week trial by Nakazaki, Mah, Sanoshy, Citrolo and Watanabe (2021) tested citicolineat 500 mg daily in 100 healthy adults aged 50–85 with age-associated memory impairment. Those taking citicoline showed significantly greater improvements in episodic memory (Paired Associate test: mean 0.15 vs. 0.06, p=0.0025) and composite memory scores (mean 3.78 vs. 0.72, p=0.0052) compared to placebo at 12 weeks. PubMed 33978188

French maritime pine bark extract — 8 to 24 weeks across published trials

Yang, Liao, Zhu, Liao and Rohdewald (2007) enrolled 200 perimenopausal women in a randomised, double-blind, placebo-controlled trial using 200 mg pine bark daily. Of the 200 enrolled, 155 completed the study. Outcomes assessed included climacteric symptom scores (Women's Health Questionnaire), antioxidative status, and lipid profile. All measured climacteric outcomes improved, antioxidative status increased, and LDL/HDL ratio improved favourably in the pine bark group. Duration of this trial was six months. No side effects were recorded. PubMed 17653885

A shorter 8-week trial by Errichi et al. (2011) tested 100 mg pine bark daily in 38 women in menopausal transition against a control group of 32 comparable women. Symptom scores for the six most common measured outcomes decreased from an average of 2.67/4 to 1.45/4 in the pine bark group, while the control group showed no change (2.72/4 to 2.73/4). Oxidative stress markers were significantly lower at both four and eight weeks in the pine bark group (p<0.05 and p=0.022, respectively). PubMed 22108479

Three reasons a supplement might not be working

Beyond timing, there are two other explanations worth examining honestly before concluding that an ingredient "doesn't work".

1. The ingredient has no quality evidence behind it for this population. A large proportion of ingredients in the perimenopause supplement market have never been studied in peri- or postmenopausal women specifically. Evidence from other populations — younger adults, athletes, people with neurological conditions — does not automatically transfer. If you cannot find a published randomised controlled trial in a population that resembles you, treating that ingredient as proven is a stretch.

2. The dose is below the research dose. This is the more common failure mode for ingredients that do have evidence. A study shows benefit at 500 mg. The product contains 50 mg. The dose is one-tenth of what was studied, but the label lists the ingredient as if it is equivalent. This practice is sometimes called "fairy dusting" — enough of an ingredient to justify its presence on the label, not enough to replicate what the trial found. Without knowing the exact dose per ingredient in a product, it is not possible to know whether the dose matches any published trial.

3. You are evaluating before the trial window has closed. As the research above shows, meaningful changes in brain creatine accumulation and cognitive performance measures were detected at eight weeks in CONCRET-MENOPA. Changes in citicoline's effect on frontal lobe bioenergetics required six weeks to become statistically significant. If someone assesses their supplement at week two or three, they are not in the measurement window the research used. That is not a product failure; it is a timing mismatch.

How timing works in The Krevie Routine

The Krevie Routine combines The Foundation and Creatine Companion. Every ingredient is dosed to match the published trial in which it was studied. Creatine HCl at 1,500 mg per day matches the medium-dose arm of CONCRET-MENOPA — the arm that produced statistically significant results at eight weeks. citicolineat 500 mg matches both the Silveri et al. (2008) six-week bioenergetics study and the Nakazaki et al. (2021) twelve-week memory trial.

The implication is practical: eight weeks is the minimum window for a fair evaluation of The Krevie Routine. That is not a marketing disclaimer — it is what the research on which the product is built actually measured.

The Krevie Routine — The Foundation + Creatine Companion. Each ingredient dosed to match its primary published clinical trial. View The Krevie Routine.

Frequently asked questions

How long should I take a perimenopause supplement before deciding if it works?

The standard clinical trial window for perimenopause supplements is 8 to 12 weeks. The CONCRET-MENOPA trial, which studied creatine HCl in perimenopausal and menopausal women, ran for eight weeks. Citicoline research measuring frontal lobe changes ran for six weeks. pine bark trials in perimenopausal women ran for eight weeks to six months. Evaluating a supplement at fewer than eight weeks means you are outside the research window used to detect an effect.

Why do supplement trials choose 8 or 12 weeks specifically?

Eight weeks gives researchers enough time for a nutrient to accumulate in target tissues, alter a physiological process, and produce a statistically detectable change in a measured outcome. Shorter trials risk capturing noise rather than signal. Twelve weeks is used when the mechanism requires longer accumulation — for example, changes in brain creatine stores or structural changes to cell membranes. The duration reflects the biology of the ingredient, not arbitrary convenience.

What is the difference between "I feel better" and "the research measured an effect"?

Clinical trials measure specific, quantifiable outcomes — reaction time, memory scores, blood markers, bioenergetics on brain imaging. These are objective. "Feeling better" is subjective and impossible to verify in a published trial without a validated scale. Krevie's content focuses on what trials measured, because that is what is verifiable. That is not a limitation — it is what allows you to compare a product's dose against a published standard.

If I take double the dose, will it work in half the time?

Not necessarily, and in some cases more is not better. In the Silveri et al. (2008) citicoline trial, the 500 mg dose produced larger effects than the 2,000 mg dose on frontal lobe bioenergetics. The CONCRET-MENOPA trial found that the medium dose of 1,500 mg creatine HCl outperformed the low dose and the combination supplement. Dose-response relationships are not always linear, which is one reason matching the research dose specifically matters more than simply maximising the dose.

Does a supplement with more ingredients always perform better?

There is no evidence that a higher ingredient count improves outcomes. A product with twelve ingredients at sub-research doses will not outperform a product with four ingredients at their research doses. Outcome measures in published trials are tied to specific doses of specific ingredients. Adding more ingredients to a formula below their individual research doses dilutes the budget across a wider ingredient list without replicating any trial's conditions.

References

Korovljev D, Ostojic J, Panic J, et al. The Effects of 8-Week Creatine Hydrochloride and Creatine Ethyl Ester Supplementation on Cognition, Clinical Outcomes, and Brain Creatine Levels in Perimenopausal and Menopausal Women (CONCRET-MENOPA): A Randomized Controlled Trial. 2026. PubMed 40854087
Silveri MM, Dikan J, Ross AJ, Jensen JE, Kamiya T, Kawada Y, Renshaw PF, Yurgelun-Todd DA. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008;21(10):1066–75. PubMed 18816480
Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Nutr. 2021;151(8):2153–2160. PubMed 33978188
Yang HM, Liao MF, Zhu SY, Liao MN, Rohdewald P. A randomised, double-blind, placebo-controlled trial on the effect of pine bark on the climacteric syndrome in peri-menopausal women. Acta Obstet Gynecol Scand. 2007;86(8):978–85. PubMed 17653885
Errichi S, Bottari A, Belcaro G, et al. Supplementation with French maritime pine bark extract improves signs and symptoms of menopausal transition. Panminerva Med. 2011;53(3 Suppl 1):65–70. PubMed 22108479

Food supplements are not a substitute for a varied, balanced diet and a healthy lifestyle. Do not exceed the recommended daily dose. Always speak to your GP if you are taking medication or have a medical condition.